Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Debt
Short-term and long-term borrowings combined.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt broadly unchanged from a year ago
Total debt stood at $39K at the end of Q1 FY2026, up 0.0% from a year earlier and down 50.0% from the prior quarter. Over 3 fiscal years it compounded at -28.2% a year.
Context
- Total debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 78K USD
- Year-over-year change
- +0.0%
- 4-year CAGR
- -31.2%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78K | +0.0% |
| FY2024 | 2024-12-31 | 78K | +20.0% |
| FY2023 | 2023-12-31 | 65K | -69.2% |
| FY2022 | 2022-12-31 | 211K | -39.4% |
| FY2021 | 2021-12-31 | 348K | — |
Total Debt vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total debt of $39K is the 10th highest of the 11 companies compared; the peer median is $29.28M.
- Its year-over-year change of +0.0% is the 5th highest of 10, against a peer median of -12.7%.
- Total debt amounts to 0.0% of total assets for SGMT, versus a peer median of 12.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.73B | +91265.7% | -7.6% | 1.7% | |
| Mar 2026 | $65.9M | +315.8% | +9.0% | 59.6% | |
| Mar 2026 | $49.75M | -12.7% | +25.2% | 14.8% | |
| Mar 2026 | $41.99M | +20.5% | -7.1% | 18.9% | |
| Mar 2026 | $34.57M | -17.7% | +16.4% | 15.8% | |
| Mar 2026 | $23.99M | -43.8% | -35.9% | 9.8% | |
| Mar 2026 | $14.95M | +50.1% | -2.6% | 45.2% | |
| Mar 2026 | $2.49M | -17.5% | -8.8% | 1.1% | |
| Mar 2026 | $634K | -56.1% | -35.4% | 0.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $39K | +0.0% | -28.2% | 0.0% |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding SGMT) | $29.28M | -12.7% | -7.1% | 12.3% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.